Chronic inflammation of blood vessels could help explain high childhood mortality in malaria regions

Recurrent episodes of malaria cause chronic inflammation in blood vessels that might predispose to future infections and may increase susceptibility to cardiovascular disease, a Wellcome Trust study in Malawian children finds.

The findings could explain the indirect burden of on childhood deaths in areas where the disease is highly prevalent and children experience multiple clinical episodes of malaria in a year.

Malaria is caused by infection with a parasite that starts by infecting the liver and then moves into red blood cells. The most deadly of the malaria parasites is Plasmodium falciparum because of its ability to cause inflammation in blood vessel walls, making them more sticky so that the infected red blood cells can cling to the sides. Being able to stick to the blood vessels in allows the parasite to hide away from the immune system, a process called . When it occurs in the brain it causes a more severe form of the disease called , associated with seizures, coma and sometimes death.

It was thought that the changes in the that enable the infected to stick would resolve quickly once the cells had been cleared; however, the new findings show that inflammation is still present up to one month later.

Researchers from the Malawi-Liverpool-Wellcome Clinical Research Programme at the University of Malawi College of Medicine in Blantyre, Malawi, looked at 190 children with uncomplicated, mild or cerebral malaria compared with healthy children of the same age. They found that the changes were most pronounced in children with cerebral malaria, with the levels of one inflammatory molecule remaining 22 times higher than in healthy controls one month after the initial infection.

Dr Chris Moxon, a Wellcome Trust Clinical PhD Fellow and first author of the study, explains: "These findings suggest that children who live in areas of high malaria transmission have persistently inflamed blood vessels, and that could have significant effects on their long term health. It could leave them more susceptible to repeated and more severe infections with malaria, but also with other bacteria and viruses. Chronic changes to the like these could an important contributing factor to cardiovascular disease later in life."

Professor Rob Heyderman, lead author and Director of MLW, added: "If follow-up studies in other populations confirm these findings, we should consider whether existing anti-inflammatory drugs such as statins may be able to limit these effects. Short courses of statins could be targeted to children with severe and recurrent disease to try and limit the severity of future infections but this would need to be evaluated in well-conducted clinical trials."

Around 300 million clinical episodes of malaria are caused by infection with the parasite P. falciparum each year. The disease is transmitted by mosquitos and children living in areas where the parasite is particularly prevalent may receive more than one infective bite per day, resulting in repeated clinical episodes of malaria over the course of the year.

Studies have shown that reducing malaria transmission in a population such as this can reduce the number of childhood deaths from any cause by up to 70%, an effect that is much greater than can be explained by reducing malaria alone. The findings from this new study, published today in the Journal of Infectious Diseases, could offer some explanation for the unexplained mortality in areas where is high.

More information: C.A. Moxon et al. Persistent endothelial activation and inflammation after Plasmodium falciparum infection in Malawian children. Journal of Infectious Diseases, 2013. [epub ahead of print]

add to favorites email to friend print save as pdf

Related Stories

Malaria's severity reset by mosquito

May 30, 2013

(Medical Xpress)—For the first time, researchers have proven that the way in which malaria is transmitted to the host affects how severe the resulting infection will be.

Researchers reveal malaria's deadly grip

Jun 05, 2013

Researchers at the University of Copenhagen, in collaboration with Seattle Biomedical Research Institute, the University of Oxford, NIMR Tanzania and Retrogenix LTD, have identified how malaria parasites ...

Australian researchers close in on malaria vaccine

Jul 02, 2013

Australian researchers said Tuesday they were closing in on a potential vaccine against malaria, with a study showing their treatment had protected mice against several strains of the disease.

Recommended for you

S.Korea detects second foot-and-mouth case

2 hours ago

South Korea on Monday reported its second case of foot-and-mouth disease in less than a week, triggering fearful memories of a devastating 2011 outbreak that forced the culling of millions of livestock.

Ebola kills Liberian doctor, 2 Americans infected

2 hours ago

(AP)—One of Liberia's most high-profile doctors has died of Ebola, officials said Sunday, and an American physician was being treated for the deadly virus, highlighting the risks facing health workers trying ...

Hepatitis C virus genotype 1 is most prevalent worldwide

3 hours ago

In one of the largest prevalence studies to date, researchers from the U.K. provide national, regional, and global genotype prevalence estimates for the hepatitis C virus (HCV). Findings published in Hepatology, a journa ...

1 in 3000 blood donors in England infected with hepatitis E

3 hours ago

The first systematic analysis of hepatitis E virus (HEV) transmission by blood components indicates that about 1 in 3000 donors in England have HEV in their plasma. The findings, published in The Lancet, suggest that around ...

Biologic treatments for RA carry similar infection risk

3 hours ago

(HealthDay)—The risk of hospitalized bacterial infections in older rheumatoid arthritis (RA) patients is similar for rituximab or abatacept compared to etanercept, although it is higher for infliximab, ...

New oral drug regimens cure hardest-to-treat hepatitis C

3 hours ago

Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according ...

User comments